Immunotherapy for pancreatic cancer
Pancreatic cancer is among the most lethal malignancies resistant to conventional therapies. The vast majority of patients is diagnosed with advanced/metastatic disease and consequently has grim prognosis. Despite the available options with nab-paclitaxel and gemcitabine or 5-fluorouracil/leucovorin/oxaliplatin, chemotherapy offers a modest survival benefit. Targeted therapy in combination with chemotherapy has not shown significant improvement in treatment outcomes. The urgent need for new therapies has turned the spotlights on immunotherapy. Immunotherapy in pancreatic cancer recruits and activates T cells which recognize tumor-specific antigens.
Preclinical models have demonstrated that chemotherapy or targeted therapy works synergistically with immunotherapy. A growing body of evidence has already been gathered regarding the efficacy of checkpoint inhibitors, vaccines, adoptive T cell therapy, monoclonal antibodies, and cytokines in patients with pancreatic cancer.
Many ongoing trials are aiming to identify treatments which could combine efficacy with limited toxicity. In this article, we review the available data concerning multiple aspects of immunotherapy in pancreatic cancer.
KeywordsImmunotherapy Pancreatic cancer Vaccines Antibodies Cytokines Checkpoint inhibitors
Compliance with ethical standards
Conflict of interest
Elias Kotteas, Muhammad Wasif Saif, and Kostas Syrigos declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- Abate-Daga D, Rosenberg SA, Morgan RA (2014) Pancreatic cancer: hurdles in the engineering of CAR-based immunotherapies. Oncoimmunology 18:e291194Google Scholar
- Anjali N, Sheetal M, Kircher M, Nimeiri HS, Benson AB, Rademaker A et al (2015) Results of the phase Ib study of ipilimumab and gemcitabine for advanced pancreas cancer. J Clin Oncol 33:(suppl; abstr e15281)Google Scholar
- Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H (2013) Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Transl Med 11:291. doi: 10.1186/1479-5876-11-291
- Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D et al (2015) Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY” phase 1-2 trial. Oncotarget 20:12796–12808CrossRefGoogle Scholar
- Dalgleish AG (2015) The IMAGE I Trial Investigators. A multicenter randomized, open-label, proof of concept, phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer. J Clin Oncol 33 (Suppl abstr 336)Google Scholar
- Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H et al (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28:3617–3622CrossRefPubMedPubMedCentralGoogle Scholar
- Latheru D, Lutz E, Bulke J, Biedrzycki B, Solt S, Onners B et al (2008) Allogenic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 14:1455–1463CrossRefGoogle Scholar
- Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J et al (2011) A lethally irradiated allogenic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: a phase II trial of safety, efficacy, and immune activation. Ann Surg 253:328–335CrossRefPubMedPubMedCentralGoogle Scholar
- Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D et al (2014) Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomized, phase 3 trial. Lancet Oncol 15:829–840CrossRefPubMedGoogle Scholar
- Morse M, Diaz LA, Azad NS, Laheru D, Haley S, Sleer LS et al (2012) A phase I/II safety study of NPC-1C: a novel, therapeutic antibody to treat pancreas and colorectal cancers. J Clin Oncol 30:(suppl, abstr 233)Google Scholar
- Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ et al (2010) Phase III study in comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial S0205. J Clin Oncol 28:3605–3610CrossRefPubMedPubMedCentralGoogle Scholar
- Roshani R, McCarthy F, Hagemann T (2013) Inflammatory cytokines in human pancreatic cancer. Med Oncol 5:81–89Google Scholar
- Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H et al (2015) Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: a randomized, placebo-controlled, phase 1 trial. Oncoimmunology 4:e1001217CrossRefPubMedPubMedCentralGoogle Scholar
- Yaginamoto H, Shiomi H, Satoi S, Mine T, Toyokawa H, Yamamoto T et al (2010) A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep 24:795–801Google Scholar